BMY Stock Gets Stronger EPS Forecast from Zacks Research

Bristol Myers Squibb Company (NYSE:BMY) – Analysts at Zacks Research boosted their Q3 2028 EPS estimates for Bristol Myers Squibb in a research note issued to investors on Thursday, September 24th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $1.17 per share for the quarter, up from their previous forecast of $1.16. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same period in the prior year, the company earned $1.46 EPS. The firm’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Several other research firms have also recently commented on BMY. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Bank of America decreased their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Finally, HSBC reissued a “hold” rating and set a $65.00 target price (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Moderate Buy” and an average target price of $67.06.

Bristol Myers Squibb Stock Down 1.6%

Shares of NYSE:BMY opened at $61.40 on Friday. The company has a 50 day moving average of $64.63 and a two-hundred day moving average of $60.25. The company has a market capitalization of $125.42 billion, a price-to-earnings ratio of 13.52, a price-to-earnings-growth ratio of 0.30 and a beta of 0.19. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lazard Asset Management LLC raised its holdings in Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after acquiring an additional 368,193 shares during the period. Callan Family Office LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $3,575,000. BlackRock Inc. boosted its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. Asset One Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at approximately $4,075,000. Finally, Kendall Capital Management bought a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $3,984,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA expanded approval of CAMZYOS (mavacamten) to include pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. The broader eligible population could support additional product growth and strengthens BMY’s commercial outlook. FDA approves expanded CAMZYOS indication
• Positive Sentiment: Strong Phase 3 data for ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma showed a statistically significant improvement in minimal residual disease-negative complete responses, potentially supporting an accelerated approval path and future pipeline value. ZENBEXUS Phase 3 data
• Positive Sentiment: Bristol Myers Squibb declared a quarterly dividend of $0.63, reinforcing its income appeal, although future dividend growth depends on cash flow generation. BMY quarterly dividend
• Neutral Sentiment: Updates on real-world studies for AUGTYRO and luspatercept, along with broader healthcare-professional outreach, provide supportive commercial and clinical evidence but do not represent major new revenue catalysts yet.
• Neutral Sentiment: Johnson & Johnson continues to generate higher quarterly revenue than BMY, while both companies have shown generally gradual revenue growth. The comparison highlights BMY’s smaller scale but does not materially change its near-term earnings outlook. Bristol Myers Squibb versus Johnson & Johnson revenue comparison
• Negative Sentiment: BMY terminated an early-stage leukemia study, removing a risky pipeline bet but also signaling diminished prospects for that program. BMY terminates early leukemia trial
• Negative Sentiment: Testing of experimental fibrosis drug admilparant involved a limited number of liver-related safety events, including a patient death. Although causation remains unclear, the report undermines confidence in the program and the broader drug class. Bristol Myers trial revisions and fibrosis-drug safety concerns
• Negative Sentiment: Analysts and investors continue to focus on the potential 2027 patent cliff affecting BMY’s largest cash generator. The resulting pressure on future cash flow could challenge the company’s 17-year dividend-growth streak and weigh on valuation. Bristol Myers Squibb dividend sustainability concerns

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.